This is a preview of subscription content, log in via an institution to check access.
References
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motojy T, Omoto E, Saito H, Ohno R, Ueda R . Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074–3080.
Schnittger S, Schoh C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, Haferlach T, Hiddeman . Analysis of FLT3 length mutation in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66.
Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T . Analysis of FLT3-activating mutation in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of a sugroups with poor prognosis. Blood 2002; 99: 4326–4335.
Beghini A, Cairoli R, Morra E, Larizza L . In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells Mol Dis 1998; 24: 262–270.
Beghini A, Larizza L, Cairoli R, Morra E . c-kit activating mutations and mast cell proliferation in human leukemia. Blood 1998; 92: 701–702.
Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morr E, Mecucci C . C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726–727.
Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, Vandeberghe E, Peake I, Reilly J . c-kit proto-oncogene exone 8 in-frame deletion plus insertion mutation in acute myeloid leukemia. Br J Haematol 1999; 105: 894–900.
Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thom X, Rigal-Huguet F, Lioure B, Auvrignon A, Fiere D, Reiffers J, Castaigne S, Leverger G, Harousseau Jl, Socie G, Dombret H . A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML intergroup. Blood 2002; 99: 3517–3523.
Schlenk RF, Dohner H, Pforsich M, Benner A, Fischer K, Hartmann F, Fischer JT, Weber W, Gunzer U, Pralle H, Has R . Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone. Br J Haematol 1997; 99: 386–393.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cairoli, R., Grillo, G., Beghini, A. et al. C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index. Leukemia 17, 471–472 (2003). https://doi.org/10.1038/sj.leu.2402795
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402795
- Springer Nature Limited
This article is cited by
-
Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia
Clinical Pharmacokinetics (2022)
-
Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia
Leukemia (2011)
-
AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2
Leukemia (2009)
-
Interactive diagnostics in the indication to allogeneic SCT in AML
Bone Marrow Transplantation (2009)
-
Complementing mutations in core binding factor leukemias: from mouse models to clinical applications
Oncogene (2008)